Heplatinum Pharmaceutical-B (02142): Partner Solstice Oncology completed $225 million Series A financing and officially launched operations

Zhitong Finance App News and Platinum Pharmaceutical-B (02142) announced that the company's partner company Solstice Oncology (Solstice) has completed Series A financing of 225 million US dollars and officially started operations. The funding round was led by RA Capital Management, with participation from Canaan Partners, Forbion and other investors.

Solstice is a clinical-stage oncology immunology company dedicated to intervening in cancer earlier in the new adjuvant treatment phase. Solstice is promoting its main drug candidate, prusubimab, a second-generation Fc enhanced antibody with differentiated properties targeting cytotoxic T lymphocyte-associated protein 4 (CTLA-4). It is currently being promoted in two clinical indications. One of them is microsatellite-stable (MSS) colon cancer, and the other indication has not been disclosed. A phase 2 clinical study is evaluating the efficacy of prusubimab combined with pabolizumab on MSS clinical stage II-III colon cancer in the new adjuvant treatment. MSS is the most common subtype of colon cancer, and so far this patient group has not benefited from immunotherapy. The phase 2 clinical trial is expected to start enrolling patients in the early fourth quarter of 2026, and the study data is expected to be available in the second half of 2027.